Microbicides for sexually transmitted diseases. The results of the first efficacy trial of an ARV-based microbicide. The VOICE trial is testing 1% tenofovir. Microbicide Trials Network Statement on Decision to Discontinue Use of Oral Tenofovir. HIV Prevention Trial Milestone: VOICE Study Completes Enrollment of 5,000. Wednesday, September 28, 2011. NIAID Statement: NIH modifies . Oral tenofovir discontinued in clinical trial. Low Adherence in Vaginal Microbicide Gel Trials? Opinions of Former Trial Participants on Improving Adherence Lori Miller, MHS PhD Student London School of Hygiene. Original Article from The New England Journal of Medicine — Tenofovir-Based. The aim of the VOICE trial was to estimate. The study was conducted from September 2. August 2. 01. 2. Results, first reported in March 2. Young, unmarried women were least likely to use study products and the most likely to acquire HIV, indicating the urgent need for safe, effective and practical HIV prevention methods women will actually use. For many women, drug was not detected in any blood sample taken at any time during the study, suggesting they may have never used the products at all. However, among women in the tenofovir gel group whose blood tests indicated use of the gel, HIV risk appeared to be reduced significantly, additional analysis showed. VOICE also included three sub- studies: VOICE B (Bone Mineral Density), VOICE C (Household and Community Factors Associated with Adherence), and VOICE D, which looked to better understand women’s actual use of study products and sexual behavior during their participation in VOICE. Results. Final results of the HIV prevention study VOICE are published in NEJM0. February- 2. 01. 5VOICE Q& A4- February- 2. Women who took part in VOICE study speak up about why they didn’t use the HIV prevention products being tested. October- 2. 01. 4New results from VOICE associates tenofovir gel use with lower HSV- 2 risk in women. October- 2. 01. 4Secondary Analysis of VOICE: Injectable Contraception and HIV Risk Q& A3. March- 2. 01. 4First Comparison Between Injectable Contraceptives DMPA and NET- EN Suggests Some Women Using DMPA Were at Higher Risk of Acquiring HIV4- March- 2. Behavioral Measures of Product Use Didn’t Measure Up in VOICE HIV Prevention Trial, Report the Study’s Researchers. March- 2. 01. 4Daily HIV Prevention Approaches Didn’t Work for African Women in the VOICE Study. March- 2. 01. 3Fact sheet – The VOICE C and VOICE D Social and Behavioral Research Sub- studies: Looking for answers about adherence and the women in VOICE 4- September- 2. VOICE Fact Sheet – Understanding the Results of VOICE4- March- 2. NIAID Press Release on VOICE Results. March- 2. 01. 3Other Study Milestones. Microbicide Trials Network Statement on Decision to Discontinue Use of Tenofovir Gel in VOICE, a Major HIV Prevention Study in Women. November- 2. 01. 1Questions and Answers on Decision to Modify VOICE, Outcome of November 1. DSMB Review. 25- November- 2. Microbicide Trials Network Statement on Decision to Discontinue Use of Oral Tenofovir Tablets in VOICE, a Major HIV Prevention Study in Women. September- 2. 01. Questions and Answers on Decision to Modify VOICE, Outcome of September 1. DSMB Review. 28- September- 2. HIV Prevention Trial Milestone: VOICE Study Completes Enrollment of 5,0. Women. 6- June- 2. VOICE Study, a major HIV prevention trial for women, is launched in Zimbabwe. September- 2. 00. NIAID Press Release on start of VOICE1. September- 2. 00. HIV prevention trial of ARV- based strategies to begin next month. July- 2. 00. 9VOICE and Related Trials. Questions and Answers about the CDC TDF2 Study and VOICE1. July- 2. 01. 1VOICE Study will Continue as it Considers What Action to Take After Results of Two Trials. July- 2. 01. 1Questions and Answers about Partners Pr. EP and VOICE1. 3- July- 2. Microbicide Trials Network Statement on the status of VOICE Study following announcement to close the FEM- Pr. EP trial. 18- April- 2. Trial shows ARVs can prevent HIV in men who have sex with men, making VOICE Study in women more important than ever. November- 2. 01. 0Results of CAPRISA 0. HIV prevention, say MTN researchers conducting VOICE1. July- 2. 01. 0Understanding Resistance. Please note that the information contained in the following materials may have changed since publication. Drug Resistance and ARV- Based Prevention Fact Sheet. Drug Resistance and ARV- Based Prevention Q& ADiagrams: Video: Drug Resistance and ARV- Based Prevention. See Also MTN- 0. VOICE) Study Protocol. MTN- 0. 03 B (VOICE B) Study Protocol. MTN- 0. 03 C (VOICE C) Study Protocol. MTN- 0. 03 D (VOICE D) Study Protocol.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
September 2017
Categories |